Heinzerling Amy, Armatas Christina, Karmarkar Ellora, Attfield Kathleen, Guo Weihong, Wang Yun, Vrdoljak Gordon, Moezzi Bahman, Xu Dadong, Wagner Jeff, Fowles Jefferson, Dean Charity, Cummings Kristin J, Wilken Jason A
Center for Healthy Communities, California Department of Public Health, Richmond.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
JAMA Intern Med. 2020 Jun 1;180(6):861-869. doi: 10.1001/jamainternmed.2020.0664.
Since August 2019, more than 2700 patients have been hospitalized with e-cigarette, or vaping, product use-associated lung injury (EVALI) across the United States. This report describes the outbreak in California, a state with one of the highest case counts and with a legal adult-use (recreational) cannabis market.
To present clinical characteristics and vaping product exposures of patients with EVALI in California.
DESIGN, SETTING, AND PARTICIPANTS: Case series describing epidemiologic and laboratory data from 160 hospitalized patients with EVALI reported to the California Department of Public Health by local health departments, who received reports from treating clinicians, from August 7 through November 8, 2019.
Standardized patient interviews were conducted to assess vaping products used, frequency of use, and method of product acquisition. Vaping products provided by a subset of patients were tested for active ingredients and other substances.
Demographic and clinical characteristics, level of care, and outcomes of hospitalization were obtained from medical record review.
Among 160 patients with EVALI, 99 (62%) were male, and the median age was 27 years (range, 14-70 years). Of 156 patients with data available, 71 (46%) were admitted to an intensive care unit, and 46 (29%) required mechanical ventilation. Four in-hospital deaths occurred. Of 86 patients interviewed, 71 (83%) reported vaping tetrahydrocannabinol (THC)-containing products, 36 (43%) cannabidiol (CBD)-containing products, and 39 (47%) nicotine-containing products. Sixty-five of 87 (75%) THC-containing products were reported as obtained from informal sources, such as friends, acquaintances, or unlicensed retailers. Of 87 vaping products tested from 24 patients, 49 (56%) contained THC. Vitamin E or vitamin E acetate was found in 41 (84%) of the THC-containing products and no nicotine products.
Patients' clinical outcomes and vaping behaviors, including predominant use of THC-containing products from informal sources, are similar to those reported by other states, despite California's legal recreational cannabis market. While most THC products tested contained vitamin E or vitamin E acetate, other underlying cause(s) of injury remain possible. The California Department of Public Health recommends that individuals refrain from using any vaping or e-cigarette products, particularly THC-containing products from informal sources, while this investigation is ongoing.
自2019年8月以来,美国已有超过2700名患者因使用电子烟或雾化产品相关肺损伤(EVALI)而住院。本报告描述了加利福尼亚州的疫情情况,该州是病例数最多的州之一,且拥有合法的成人使用(娱乐性)大麻市场。
介绍加利福尼亚州EVALI患者的临床特征和雾化产品暴露情况。
设计、地点和参与者:病例系列,描述了2019年8月7日至11月8日当地卫生部门向加利福尼亚州公共卫生部报告的160例住院EVALI患者的流行病学和实验室数据,这些数据由治疗临床医生上报。
进行标准化的患者访谈,以评估使用的雾化产品、使用频率和产品获取方式。对部分患者提供的雾化产品进行活性成分和其他物质检测。
通过病历审查获取人口统计学和临床特征、护理级别及住院结局。
在160例EVALI患者中,99例(62%)为男性,中位年龄为27岁(范围14 - 70岁)。在有数据可用的156例患者中,71例(46%)入住重症监护病房,46例(29%)需要机械通气。4例患者在住院期间死亡。在接受访谈的86例患者中,71例(83%)报告使用含四氢大麻酚(THC)的产品,36例(43%)使用含大麻二酚(CBD)的产品,39例(47%)使用含尼古丁的产品。87例含THC产品中的65例(75%)报告是从朋友、熟人或无证零售商等非正式渠道获得的。在对24例患者送检的87个雾化产品中,49个(56%)含有THC。在含THC的产品中有41个(84%)检测出维生素E或维生素E醋酸酯,含尼古丁产品中未检测到。
尽管加利福尼亚州有合法娱乐性大麻市场,但患者的临床结局和雾化行为,包括主要从非正式渠道使用含THC产品,与其他州报告的情况相似。虽然大多数检测的THC产品含有维生素E或维生素E醋酸酯,但仍可能存在其他潜在损伤原因。在本次调查进行期间,加利福尼亚州公共卫生部建议个人避免使用任何雾化或电子烟产品,特别是从非正式渠道获得的含THC产品。